CTI BioPharma Corp. (CTIC) Raised At WallachBeth Capital

CTI BioPharma Corp. (CTIC) was raised to ‘Buy’ from ‘Hold’ and had its $4.50 price target reiterated at WallachBeth Capital on Wednesday. The firm, whose target price suggests a potential upside of 79.28% from the company’s previous close, believes ticker’s current price-per-share, represents an opportunity for sophisticated investors to accumulate shares. A limited number of […] View the full post at: CTI BioPharma Corp. (CTIC) Raised At WallachBeth Capital Related posts: The Supervisory Capital Assessment Program: Overview of Results Rents in London Crashing to 1991 Levels Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale